ACTRN12617001119381招募中未知
Circulating Tumour DNA as a Marker of Residual Disease and Response to Adjuvant Chemotherapy in Stage I - IV Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer (EOC)
Walter and Eliza Hall Institute of Medical Research0 个研究点目标入组 100 人开始时间: 2017年7月31日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- Female
入选标准
- •1. Patients that have had primary debulking surgery for curatively resected stage I-IV high grade serous, endometrioid or clear cell carcinoma, or carcinosarcoma of the ovary, fallopian tube or primary peritoneum. Stage IV patients can only be included in the study if they have had a complete resection of all macroscopic disease with no residual disease.
- •Patients commencing neoadjuvant chemotherapy for stage I-
- •III high grade serous, endometrioid or clear cell carcinoma, or carcinosarcoma of the ovary, fallopian tube or primary peritoneum. Women must be planned to undergo interim debulking surgery.
- •2. A representative tumour sample can be made available for molecular testing after surgery or a core biopsy pre neoadjuvant chemotherapy if available.
- •3. Fit and planned for adjuvant chemotherapy.
排除标准
- •1. History of another primary cancer within the last 3 years,
- •with the exception of non-melanomatous skin cancer,
- •carcinoma in situ of the cervix and fully resected stage1a
- •endometrial cancer
- •2. Patients with EOC of mucinous subtype and sarcoma
- •3. Patients with Stage IV disease who have residual disease
- •4. Patients <18 years
研究者
相似试验
尚未招募
不适用
Circulating Tumour DNA as a Marker of Complete Pathological Response and Long Term Outcome for Locally Advanced Rectal Cancer Treated with Pre-operative ChemoradiotherapyACTRN12612000327886udwig Institute for Cancer Research320
进行中（未招募）
不适用
Circulating Tumour DNA as a Marker of Residual Disease & Response to Adjuvant Chemotherapy in Stage I-IV Ovarian CancerOvarian CancerNCT03691012Walter and Eliza Hall Institute of Medical Research118
招募中
不适用
Circulating tumor DNA as a noninvasive biomarker in patients with thyroid cancerC73Malignant neoplasm of thyroid glandDRKS00022441niversitätsklinikum Freiburg75
招募中
不适用
Circulating tumor DNA as a noninvasive biomarker in patients with Non-Hodgkin Lymphoma (NHL)C83.3C85Diffuse large B-cell lymphomaOther and unspecified types of non-Hodgkin lymphomaDRKS00024180niversitätsklinikum Freiburg200
尚未招募
不适用
Circulating tumor DNA as biomarker for perihilar cholangiocarcinomaPerihilar cholangiocarcinoma/ Perihilair cholangiocarcinoomKlatskin-tumorBiomarkerCirculating tumor DNA /Circulerend tumor DNA (ctDNA)NL-OMON27478AMC20